Company ProfilePremium

Qianhai Health Holdings Limited

Company Profile Analysis

Ticker: 0911.HK前海健康控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Qianhai Health Holdings Limited - Company showcase

Year Founded & Workforce

1989

19 Employees

Qianhai Health Holdings Limited logo

Qianhai Health Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Qianhai Health Holdings Limited Overview

MetricFY2023FY2024FY2025
Employees (year-end, headcount)—1619

Qianhai Health Holdings is, despite its name, today essentially a Hong Kong-based independent trader of memory semiconductors — predominantly NAND flash wafers, embedded multi-chip package (eMCP) memory and general electronic components — that sources from upstream distributors and resells to a highly concentrated group of trade customers, with a small, recently revived sideline in ginseng wine, skin-care and health products. Originally the Hang Fat American-ginseng wholesaler, the group pivoted into electronic components in July 2019 under its current controlling shareholder, Mr. Huang Zhiqun, a veteran electronic-components distributor. The business is thin-margin (gross margin 3.5% in FY2025), asset-light (19 staff, one office and warehouse), debt-free, and highly exposed to memory price cycles, as demonstrated by a HK$233.7 M loss in FY2022 on inventory and onerous-contract write-downs. Its equity value is roughly a quarter of book, reflecting cyclicality, customer concentration (top customer 69% of FY2025 sales) and an unresolved receivership over the controlling 52.67% stake.


The company's own description (paraphrased from AR2025)

In AR2025 the board describes the group as principally engaged in the sale of electronic component products (the "Electronic Component Business") and health-care products and food (the "Health-Care Business"). The electronic components operation is characterised as a seller of semiconductors and other electronic components specialising in digital storage products such as NAND flash wafers and general electronic components, with a business model built on identifying, sourcing and distributing products from reputable upstream manufacturers. The company says it benefits from a broad, established customer and supplier base, many with long-standing relationships with the directors, and that its suppliers are mainly component distributors and electronics/IT corporations. For the health-care business, the company says it re-entered the health products sector during 2025 with a refined offering of ginseng wine (positioned as a premium dietary supplement), skin-care and body-care products, and is still building supplier networks, customer relationships and market presence.

Independent characterisation

Stripped of the label, Qianhai Health is a principal-basis memory-chip trading house operating in the Hong Kong spot and contract market for NAND flash. Several features define it:

  1. No manufacturing, no design, no proprietary IP. The group adds value through procurement access, working capital, warehousing/quality control and the directors' relationships. The 2022 interim report mentioned value-added services such as warehousing and quality control for customers.

  2. Principal risk-taking on inventory. The group alternates between (i) back-to-back procurement matched to confirmed customer orders and (ii) "strategic bulk procurement" based on management's price view. In FY2025 it explicitly shifted toward bulk buying to capture rising NAND prices (AR2025). This is effectively a directional position on memory prices; it generated a HK$230.0 M inventory provision and HK$93.2 M onerous-contract provision in FY2022 when the cycle turned (FY2023 inside-information announcement, 8 Feb 2024).

  3. Prepayment-heavy working capital. Suppliers require deposits of 15–20% (FY2025; 15–30% in FY2024) within three business days of an order, with the balance paid before delivery (AR2025). Customers receive 30–180 days' credit. The company therefore finances the cycle on both sides out of equity.

  4. Extreme concentration. In FY2025 the largest customer accounted for ~69% and the top five ~92% of sales; the largest supplier ~26% and top five ~90% of purchases (AR2025). None are related parties according to the directors.

  5. Single-geography revenue recognition. All revenue is recognised in Hong Kong based on the location of delivery (FY2024 RA note 3), though end-demand is driven by PRC and Asian electronics manufacturers.

  6. Health-care segment is residual. It contributed ~10% of FY2025 revenue (AR2025) but only HK$2.25 M (≈2%) in 1H2026 (1H2026 IR).

Revenue model mix

Revenue typeShare of FY2025 revenueComment
Product sales — electronic components (principal basis, point-in-time recognition)>90%NAND flash wafers, eMCP memory, other components (AR2025; FY2024 RA note 3)
Product sales — health-care products and food~10%Ginseng wine, skin-care, body-care, Chinese herbal products (AR2025)
Services0%No separately reported service revenue
Subscription / licensing0%—
Interest income (other income, not revenue)De minimisHK$0.22 M interest on short-term third-party loans in FY2024 (FY2024 RA note 4)

Value-chain position

Upstream memory manufacturers (Samsung, SK hynix, Kioxia/Western Digital (now Sandisk), Micron, YMTC — not named by the company) → franchised/authorised distributors and large PRC trading companies (the group's suppliers) → Qianhai Health (independent trader/broker, Hong Kong) → module makers, SSD/eMMC/USB assemblers, OEM/ODM manufacturers and other traders (the group's customers, mostly PRC/Asia, delivered in Hong Kong) → consumer electronics, data-centre SSD, mobile, automotive end-markets.

In 2022 the group signed a master sale and purchase agreement with what it described as one of the largest trading companies in the PRC as a supplier, securing a steady source of components (Interim Report 2022). Management's stated aspiration (AR2025) is to move up the chain into manufacturing facilities in the PRC and elsewhere offering customisation, assembly, packaging and testing.

Customer types and end-markets

Customer typeEnd-markets servedEvidence
Electronics manufacturers, module houses and traders (Hong Kong delivery)Storage (SSD, eMMC/UFS, USB), mobile devices, consumer electronics, data-centre infrastructure, automotive electronicsAR2025 MD&A cites AI, 5G, data centres and automotive as demand drivers
Health-product wholesalers and retailers in Hong KongTraditional Chinese health tonics, dietary supplements, skin/body careAR2025 ESG report (sales to wholesalers and retailers in Hong Kong)

Strategy

Stated strategic themes (paraphrased from AR2025 Prospects and FY2024 RA Future Prospects)

  1. Ride structural semiconductor growth — third-generation semiconductors, 5G, AI and automotive electronics are framed as long-term growth drivers; management expects the NAND wafer shortage to persist in the near term and intends to use supplier relationships to secure inventory where possible.

  2. Move into value-added manufacturing — plan to invest in new manufacturing facilities in the PRC and elsewhere, enabling technical support, product customisation, assembly, packaging and testing.

  3. R&D partnerships and own products — collaboration with technology companies and research institutions; FY2024 RA also referred to sourcing R&D investments to create its own products and build brand influence.

  4. Rebuild the health-care segment — talks with potential partners in skincare and healthcare supplements; sourcing body-care products; pursuit of authorised-distributor relationships with manufacturers.

  5. Supply-chain resilience — reduce exposure to geopolitical issues and material shortages.

  6. Inorganic growth — pursue investments and acquisitions of promising projects for medium- to long-term returns.

  7. Product-agency optimisation (FY2024 RA) — optimise product agency layout, expand the product matrix and strengthen supply-chain cooperation.

Initiatives announced or executed in the last 24 months

InitiativeDateStatus / evidenceTargets
Shift from back-to-back to strategic bulk procurementFY2025Executed; inventory rebuilt to HK$231 M by Jun 2026None disclosed
Ginseng wine, skin-care launch (health-care re-entry)FY2025~10% of FY2025 revenue; HK$2.25 M in 1H2026None disclosed
Share consolidation (10:1)20 May 2024Completed—
New share option scheme27 Jun 2024Adopted; no grantsMandate 16.94 M shares
Disposal of Huge Hope Group28 Nov 2024Completed; HK$51.9 M gain—
Board reconstitution (two new EDs, new audit chair)Aug–Nov 2024Completed—
Cost control1H2026Admin expenses −27.9% to HK$6.8 MNone disclosed
PRC manufacturing facilitiesAnnounced in AR2025 (Apr 2026)No capex committed; AR2025 states no specific plans for material investments or capital assetsNone disclosed
ESG — carbon/energyFY2025Target to keep emissions and energy "at a similar low level"Qualitative only

Medium-term financial targets / guidance

The company provides no quantitative medium-term targets or guidance. Its only forward-looking quantitative disclosures are statutory profit alerts (e.g., 13 Feb 2026 positive profit alert for FY2025; 24 Jul 2026 profit warning guiding a 35–45% decline in 1H2026 profit — actual decline 36.7%).

Products & Services

The company does not publish a product catalogue, price list or brand architecture. The following is the complete set of product lines disclosed in filings since 2016.

Electronic component products segment

Product lineDescription & capabilitiesTarget customerFirst disclosed / latestPricing modelFlagship / named offerings
NAND flash wafersThin silicon wafers carrying NAND flash dies, the core input for flash ICs (SSD, eMMC/UFS, USB, cards). AR2025 notes TLC wafers saw the sharpest shortages in 2025Module makers, SSD/eMMC assemblers, packaging houses, tradersDisclosed from FY2023–FY2024; core line in FY2025–1H2026Spot/contract market pricing; principal margins of ~3–7%Upstream brands not disclosed
eMCP memory (embedded multi-chip package)Single package combining NAND (eMMC) and mobile DRAM; used in smartphones, tablets, IoTMobile/IoT device makers and module housesDisclosed in 1H2023 and FY2024 segment definitionsMarket pricing—
General electronic componentsOther ICs and components; AR2025 records a HK$1.3 M inventory provision on long-aged "other electronic component products"Electronics manufacturers and tradersFrom July 2019Market pricing—
CPUs and semiconductors (historical)Central processing units and semiconductors described in earlier segment definitionsElectronics manufacturers2019–2022Market pricing—
Value-added services (historical, not separately charged)Warehousing and quality-control services to meet customer-specific needsTrade customersDescribed in Interim Report 2022Bundled—
Planned: customisation, assembly, packaging, testing, technical supportProposed new manufacturing facilities in the PRC and other locationsExisting customersAnnounced as a prospect in AR2025; no capex committed——

Health-care products and food segment

Product lineDescriptionTarget customerPeriodPricing modelNamed offerings
American ginseng (Panax quinquefolius) — cultivated and wildThe historical core: procurement in the US and Canada and wholesale in Hong KongHong Kong wholesalers/retailers1989–2023 (disclosed through AR2021–AR2023)Wholesale—
Chinese herbal medicinesTraditional herbal productsWholesalers/retailers2019–presentWholesale—
Ginseng wine / health beveragesPositioned as a premium dietary supplement for health-conscious consumers; marks the 2025 "re-entry" into health productsWholesalers/retailersSourcing from FY2024; first sales FY2025Wholesale—
Healthcare wine (historical)Listed among major products in FY2018Wholesalers/retailers2,018Wholesale—
Skin-care productsCommenced trading in 2025Wholesalers/retailers2019–2021; re-launched 2025Wholesale—
Body-care products & supplementsManagement negotiating authorised-distributor arrangements with manufacturersWholesalers/retailersPipeline (AR2025)——

Discontinued businesses

BusinessDescriptionStatus
Money lending (Qianhai Health Finance Ltd)Licensed money lender from Aug 2015; loan and interest receivables disclosed in AR2018–AR2019No longer reported as an activity
PRC "big health" projectsHospitals, health check centres, senior housing, health resorts, Hangzhou platform (AR2017)Not pursued in recent filings
Joint venture (equity-accounted)Share of results of a joint venture referenced in 1H2021 and 1H2022 announcements—

Financial Narrative

All figures HK$ M unless stated. Primary sources: AR2021, AR2022 financial highlights; FY2023 RA; FY2024 RA; AR2025. FY2021–FY2022 EPS restated by analyst for the 10:1 consolidation (FY2022 reported −13.79 HK cents pre-consolidation).

Income statement: notes and sources

FY2021 and FY2022 EBITDA from TipRanks aggregation (HK$2.06 M and HK$−231.24 M); FY2023 EBITDA reconciles to TipRanks (−50.23). FY2024 EBITDA includes the HK$51.9 M disposal gain, HK$60.4 M onerous-contract provision and HK$4.2 M PPE impairment. FY2025 cost of sales derived (revenue − gross profit).

Growth

Revenue CAGR FY2021–FY2025: +24.3% (from HK$283.4 M to HK$677.1 M). CAGR FY2020–FY2025: −2.3% (from HK$760.7 M). The choice of base year transforms the conclusion — the business has no secular growth trend; it oscillates with the memory cycle.

Balance sheet: notes and sources

Goodwill/intangibles: none disclosed in the balance sheets reviewed (FY2023–FY2024 show PPE as the only non-current asset). FY2021–FY2022 NAV per share restated by analyst from reported HK$0.40 and HK$0.26. FY2025 net current assets per AR2025. Note: AR2025 MD&A states equity per share as "HK2.3 cents" — this appears to be a typographical error; the financial highlights show HK$2.31.

Interim balance sheet (30 Jun 2026, 1H2026 IR): total assets HK$441.4 M (+8.1% vs Dec 2025); inventories HK$231.4 M (roughly 4x Dec 2025); cash HK$17.9 M (−70.9%); contract liabilities (customer advances) HK$32.4 M; current ratio 8.9x; no bank borrowings.

Cash flow: notes and sources

Given no borrowings, no dividends, no buybacks and no material investments (AR2025), the FY2025 cash increase of HK$38.1 M is likely dominated by operating cash flow (inventory liquidation of ~HK$134 M offset by receivables build of ~HK$124 M). No shares were repurchased in FY2024 or FY2025 (AR2025; FY2024 RA).

Ratios — analyst-derived on year-end balances: notes and sources

Current ratios for FY2023–FY2025 are as reported (FY2024 RA; AR2025). Payables are negligible (accruals ~HK$2 M) so DPO ≈ 0; supplier prepayments are an additional working-capital drain not captured in the CCC.

Half-year P&L tracker: notes and sources

1H2024 net profit derived from 1H2025's reported −69.3% decline (HK$4.774 M). 1H2023 net result not captured. Sources: 1H2022 RA; 1H2024 RA; wire summaries of 1H2025 (20 Aug 2025) and 1H2026 (12 Aug 2026) results.

Commentary on trends, inflections and drivers

Revenue. The revenue line is a function of memory-chip prices multiplied by the volume of product management can source and is willing to carry. FY2022's HK$1.96 bn peak followed the 2022 supply master agreement and a deliberate scale-up in electronics; it collapsed by 51% in FY2023 and a further 46% in FY2024 as prices fell and the group reduced volumes amid intense competition (FY2024 RA). FY2025's 30% rebound was price-driven: AR2025 reports TLC wafer prices rising more than 65% month-on-month at points in 2025, partly offset by lower volumes because upstream shortages limited what the group could buy. The 1H2026 collapse (−65.7%) is the same shortage at a more acute stage — management attributed it to manufacturers reallocating capacity to AI memory (HBM, DDR5).

Gross margin. Margins are structurally thin (3–6%) for a broker without franchise rights. The negative FY2023 margin reflects selling inventory below carrying cost. The FY2024 recovery to 5.7% came from higher-margin product mix and a Q1 2024 price rebound; FY2025 compressed to 3.5% because competition intensified even as prices rose. The 1H2026 improvement to 6.6% came from selective pricing and mix, on far lower volume.

Below gross profit — the real swing factor. Every year's bottom line has been dominated by non-recurring items: FY2022 (−HK$323 M of inventory and onerous-contract provisions), FY2024 (+HK$51.9 M disposal gain, −HK$60.4 M onerous-contract provision, −HK$4.2 M PPE impairment), FY2025 (−HK$2.6 M ECL, −HK$1.3 M inventory provision). Recurring overhead is small (administrative expenses ~HK$15–17 M/year; 1H2026 HK$6.8 M, down 27.9%). This means the group needs roughly HK$15–17 M of annual gross profit to break even before one-offs.

Balance sheet. Equity has fallen from HK$670.5 M (FY2021) to ~HK$391 M, almost entirely through the FY2022 loss. Since then it has been stable. The group is unlevered and the balance sheet is essentially a working-capital fund: at 31 Dec 2025, ~HK$327 M of HK$408 M total assets was inventory, receivables and supplier prepayments. Composition shifts violently: inventory fell from HK$329.8 M (FY2023) to HK$54.9 M (FY2025), then rebuilt to HK$231.4 M by June 2026 while cash fell to HK$17.9 M — a renewed directional bet on memory prices.

Credit risk is rising. Trade receivables more than doubled to HK$222.7 M in FY2025, against revenue up only 30%; DSO lengthened to ~120 days and ECL provisions rose to HK$2.6 M. Given the top customer accounts for ~69% of sales, a single default could erase several years of profit. A HK$2.03 M ECL reversal in 1H2026 suggests some collection progress.

Returns. ROE has not exceeded 1.5% since FY2021 and averages deeply negative over five years; the business has destroyed roughly HK$280 M of book value since FY2021.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts/servicesSegment measure reported

Electronic component products

Sale of information-technology component products

NAND flash wafers; embedded multi-chip package (eMCP) memory; other electronic components (historically also CPUs and semiconductors)

Segment result = gross profit; no segment assets/liabilities reported

Health-care products and food

Sale of health-care products and food

Chinese herbal medicines (incl. American ginseng), health drinks/ginseng wine, skin-care and body-care products

Segment result = gross profit

Revenue by Segment

Segment (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Electronic component products revenue

185.31,952.2954.1519.7—

Health-care products and food revenue

98.19.57.20—

Total revenue

283.41,961.7961.3519.7677.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Segment result (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Electronic component products gross profit

14.376.2-35.829.7—

Health-care products and food gross profit

1.70.30.20—

Total gross profit

16.076.5-35.629.723.6

Segment margin (%)

Segment margin (%)FY2021FY2022FY2023FY2024FY2025

Electronic component products gross margin

7.73.9-3.85.7—

Health-care products and food gross margin

1.82.82.4——

Group gross margin

5.73.9-3.75.73.5

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Electronic components revenue YoY growth

—953.7-51.1-45.5—

Health-care revenue YoY growth

-77.9-90.3-24.5-100.0—

Electronic components % of total revenue

65.499.599.3100.090

Health-care % of total revenue

34.60.50.70.010

Revenue by Segment (1H2022–1H2026)

Segment (HKD Mn)1H20221H20231H20241H20251H2026

Electronic components revenue

1,201.3337.2307.0338.7114.5

Health-care revenue

02.701.72.3

Electronic components gross profit

28.2-6.442.9—7.3

Health-care gross profit

000—0.5

Income Statement and Per-Share Data

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

283.41,961.7961.3519.7677.1

Cost of sales

267.41,885.2996.9490.0653.5

Gross profit

16.076.5-35.629.723.6

Other income

——0.10.2—

Other gains/(losses), net

——-0.5-12.8-1.5

ECL (provision)/reversal on receivables

——0.2-0.3-2.6

Administrative expenses

——16.615.3—

Finance costs

——0.040.02—

Operating income (EBIT, analyst-derived)

——-52.71.3—

Depreciation

2.42.42.42.4—

EBITDA (analyst-derived: EBIT + depreciation)

2.1-231.2-50.23.7—

Pre-tax income

-0.9-233.7-52.71.35.9

Income tax

00000

Net income attributable to owners

-0.9-233.7-52.71.35.9

Basic/diluted EPS (HK cents, post-consolidation basis)

-0.52-137.9-31.100.773.51

Dividends per share (HK cents)

00000

Margin Analysis (%)

Metric (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

5.73.9-3.75.73.5

Operating (EBIT) margin

——-5.50.3—

EBITDA margin

0.7-11.8-5.20.7—

Pre-tax margin

-0.3-11.9-5.50.30.9

Net margin

-0.3-11.9-5.50.30.9

Margin Analysis (%) — Revenue YoY growth

Metric (%)FY2021FY2022FY2023FY2024FY2025

Revenue YoY growth

-62.7592.2-51.0-45.930.3

Balance Sheet and Per-Share Data

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

738.6534.4478.1407.3408.4

Property, plant & equipment

——26.521.2—

Inventories

——329.8188.854.9

Trade receivables

——098.7222.7

Prepayments for inventory purchase

——102.070.649.0

Cash & cash equivalents

——19.523.361.4

Short-term bank borrowings

7.20000

Long-term debt

00000

Lease liabilities

——0.51.0—

Provision for onerous contracts

——92.218.4—

Total liabilities

68.197.794.021.717.2

Total equity

670.5436.7384.1385.6391.3

Goodwill & intangibles

00000

Net current assets (working capital)

622.4408.3357.6364.8371.6

Net debt (cash) (analyst-derived, excl. leases)

——-19.5-23.3-61.4

NAV per share (HK$, post-consolidation)

3.962.582.272.282.31

Cash Flow

Metric (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Dividends paid

00000

Share buybacks

00000

Net change in cash (analyst-derived from balance sheet)

———3.738.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

-0.1-53.5-13.70.31.5

ROA (%)

-0.1-43.7-11.00.31.5

ROIC (%, EBIT/(equity+debt−cash))

——-14.40.4—

Current ratio (x)

——4.818.122.6

Gearing — total liabilities/total assets (%)

9.218.319.75.34.2

Debt/equity (%)

1.10000

Net debt/EBITDA (x)

———-6.2—

Interest coverage (EBIT/finance cost, x)

———58—

Asset turnover (revenue/total assets, x)

0.383.672.011.281.66

Days inventory outstanding

——12114131

Days sales outstanding

——069120

Cash conversion cycle (days, excl. prepayments)

——121210151

Income Statement and Margin Analysis (%)

Metric (HKD Mn)1H20221H20231H20241H20251H2026

Revenue

1,201.3339.9307.0340.4116.8

Gross profit

28.2-6.442.914.27.7

Gross margin (%)

2.3-1.914.04.26.6

Net profit attributable

19.6—15.64.82.8

EPS (HK cents)

———2.821.68

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Region

Region (HKD Mn)FY2021FY2022FY2023FY2024FY2025

Hong Kong (point of delivery)

283.41,961.7961.3519.7677.1

Mainland China

00000

Rest of world

00000

Growth (%)

Growth (%)FY2021FY2022FY2023FY2024FY2025

Hong Kong revenue YoY growth

-62.7592.2-51.0-45.930.3

Revenue by Region (FY2023–FY2024)

Segment × geography (HKD Mn)FY2023FY2024

Electronic components — Hong Kong

954.1519.7

Health-care — Hong Kong

7.20

Share Price History

DatePriceCommentSource

~9 May 2025

0.205

Market cap ~HK$34.7 M

moomoo

Early 2026 (pre-spike)

0.285—

etnet

27 Apr 2026

0.84 intraday

More than doubled

etnet

29 Apr 2026

1.22 intraday

More than doubled; 52-week high observed

etnet

3 Jul 2026

0.66—

etnet

~8 Jul 2026

0.72

Market cap ~HK$122 M

Lixinger

15 Jul 2026

0.81—

etnet

29 Jul 2026

0.61

Last verified quote; market cap ~HK$103 M

etnet

Valuation Multiples

MultipleQianhai HealthBasis

Market capitalisation

HK$103.4 M

169.445 M shares × HK$0.61

Enterprise value

~HK$85.5 M

Market cap less HK$17.9 M cash (30 Jun 2026); no debt

P/E (TTM)

~25.8x

TTM profit ~HK$4.0 M (FY2025 HK$5.94 M − 1H2025 HK$4.77 M + 1H2026 HK$2.84 M)

P/E (FY2025)

~17.4x

—

P/B

~0.26x

Equity HK$391.3 M (Dec 2025)

EV/Sales (TTM)

~0.19x

TTM revenue ~HK$453 M

EV/EBITDA

Not computable

—

Lixinger reported (early Jul 2026, HK$0.72)

P/E 20.5x; P/B 0.31x

Lixinger

Capital Markets

ItemStatus

Dividend history

No dividends declared for FY2021–FY2025 or 1H2026 (ARs; 1H2026 IR)

Dividend policy

Board-discretionary policy considering performance, reserves, working capital, liquidity and conditions; no payout target (AR2025)

Distributable reserves

HK$258.4 M (31 Dec 2025)

Share option mandate

16,944,500 shares (10%) under 2024 scheme; none granted

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

Not applicable — no borrowings; only small lease liabilities

Analyst consensus

No sell-side coverage identified

Analyst Conclusions

Management guidance

No numerical guidance. Qualitatively, AR2025 expects the NAND wafer shortage to persist near term and positions the company to secure inventory, invest in downstream facilities and rebuild health-care. The 24 Jul 2026 profit warning (−35% to −45%) was the only quantified forward statement in 2026 and proved accurate (−36.7%).

Consensus expectations

None — no analyst coverage.

Bull case

  1. Inventory leverage to a memory super-cycle. With HK$231 M of inventory at June 2026 (vs HK$55 M at Dec 2025) and WSTS forecasting memory revenue up roughly 250% in 2026, every 10% rise in realisable value on that inventory equals ~HK$23 M — roughly four years of recent profit.

  2. Deep discount to tangible book. At ~0.26x P/B with no debt, no goodwill and HK$258 M of distributable reserves, the market prices in substantial further losses; even modest normalised ROE would justify re-rating.

  3. Change-of-control optionality. The receivership over 52.67% could lead to a sale of the control block, which in Hong Kong generally triggers a mandatory general offer to minorities — a potential catalyst.

Bear case

  1. Repeat of FY2022. The group re-loaded inventory into a price spike; a memory price correction would reproduce the FY2022 pattern (HK$323 M of provisions against equity then of HK$670 M).

  2. Concentration and credit. One customer at ~69% of sales and receivables of HK$223 M (more than half of equity) leave the company exposed to a single default.

  3. Structural disadvantage and governance overhang. Without franchise allocation, the group loses volume exactly when prices are best (FY2025, 1H2026); it has no CEO, its controlling stake is in receivership, and value creation since FY2021 has been negative.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhy it matters
Receivers' actions on the 52.67% stakeAny timeChange of control / possible general offer
Memory (NAND) spot price trajectoryContinuousDrives inventory gains/losses on HK$231 M stock
FY2026 annual results and any profit alertFeb–Mar 2027Test of inventory value and receivables quality
Receivables collection / ECL movementsFY2026 resultsCredit risk
Customer advances (HK$32.4 M contract liabilities) conversion to revenue2H2026Indicates 2H revenue recovery
Capex commitment to PRC facilitiesUnspecifiedStrategic credibility; cash use
CEO appointmentUnspecifiedGovernance
Litigation outcomes (CAD 2.8 M claim; Beijing dispute)UnspecifiedUnprovided contingent liability
Exchange queries on trading volatilityUnspecifiedRegulatory risk

Concluding analyst verdict

Qianhai Health Holdings should be analysed not as a health company but as a lightly capitalised, debt-free memory-chip trading book wrapped in a listed shell with an unstable ownership structure. The financial history is unambiguous: revenue has swung from HK$283 M to HK$1.96 bn and back to HK$677 M in four years, gross margins have ranged from −3.7% to 5.7%, and the only material profit since FY2019 came from a one-off disposal gain. Book value has shrunk by roughly 40% since FY2021, almost entirely from a single cycle turn in 2022. The core economic proposition — buying memory in bulk ahead of price moves and reselling to a handful of customers — has positive expected value only if management's timing is consistently right, and the 2022 episode shows the downside when it is not.

The current set-up is unusually binary. On one side, the group sits on inventory roughly four times its year-end 2025 level during what WSTS describes as an extraordinary memory upswing, trades at about a quarter of book, carries no debt and could become the subject of a control transaction because receivers now hold the 52.67% stake. On the other, it lacks franchise allocation, depends on one customer for most of its sales, has more than half its equity tied up in receivables, has gone seven years without a CEO, and has a board member linked to the creditor group holding the security over the control block.

For institutional investors the stock is effectively uninvestable on liquidity grounds alone (daily turnover can be in the tens of thousands of Hong Kong dollars). For special-situations investors, the thesis rests on two variables outside management's operating control: the memory price path and the outcome of the receivership. We would characterise the shares as a high-risk, event-driven option on asset value rather than a fundamental compounder, and we would require visibility on the receivers' intentions and on receivable collections before assigning weight to the book-value discount.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAge (AR2025)AppointedPrior roles / backgroundEducation

Mr. Huang Zhiqun (黃志群)

Chairman, non-executive director; authorised representative; ultimate controlling shareholder (52.67% via Explorer Rosy)

51

ED 12 Apr 2019; re-designated NED 17 Jul 2019

20+ years in electronic-components trading; ran own trading firm 1999–2003; co-founded a Hong Kong-based global component trading and distribution group in 2003 (CEO since), with presence in HK, PRC, Southeast Asia; co-founded a semiconductor manufacturing and trading group in 2005; standing director, Shenzhen Chao Shan Chamber of Commerce since Dec 2011

—

Mr. Chen Kaiben (陳凱犇)

Non-executive director

40

3 Sep 2021

ED of Solis Holdings (2227.HK) Oct 2020–Aug 2021; NED of Glory Sun Financial (1282.HK) and Glory Sun Land (299.HK) 2018–2019; Shenzhen Bao Da Financial Services; Dasheng Times Cultural Investment (600892.SH)

BBA (logistics & supply chain), Guangdong University of Foreign Studies, 2007

Mr. Chen Qi (陳琦)

Non-executive director

35

3 Sep 2021

Vice GM, operational management, Yunnan Energy Investment (HK) Co. Ltd since Jun 2020; earlier Yunnan Energy Finance Holdings and Yunnan Energy International (Singapore)

BA finance management, Yunnan University of Finance and Economics, 2015

Mr. Yuen Chee Lap Carl (源自立)

Executive director; member, remuneration & nomination committees

52

INED 29 Feb 2016; re-designated ED 23 Aug 2024

2004–May 2024 financial controller, CEO and COO of Courage Investment Group (1145.HK / SGX); US chief accountant roles 1998–2003

BBA 1997, MBA 1998, University of Houston

Mr. Tang Yu Yuan (湯裕源)

Executive director

60

1 Oct 2024

28+ years in electronic-component and semiconductor distribution with Taiwanese technology companies

BEng Electronic Engineering, "National Southeast University" in Taiwan (as stated in AR2025)

Mr. Li Wei (李偉)

INED; chair of remuneration and nomination committees; audit committee member

71

17 May 2016

25+ years establishing businesses in Asia; INED of VSTECS Holdings (856.HK) since 2007

Educated in China, Germany and Australia

Mr. Leung Chun Tung (梁振東)

INED; audit, remuneration, nomination committees

71

1 Mar 2022

39 years at Bank of China (Hong Kong), last as senior corporate loan manager

Executive MBA, Sun Yat-sen Business School / International East-West University

Ms. Wu Hung Yu (胡紅玉)

INED; audit committee chair; nomination committee (from 25 Jun 2025)

45

22 Nov 2024

Ex-international accounting firms (audit, M&A, IPOs); INED of i-Control Holdings (1402.HK) and Well Link Securities (8350.HK)

BA Accountancy, Hong Kong Polytechnic University 2003; ACCA (2008), HKICPA (2009)

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleAgeJoinedBackground

Ms. Yip Tak Yung Teresa

Chief financial officer and company secretary

442013

Ex-Deloitte; INED of Guangdong Topstar Technology (300607.SZ); HKICPA member; BBA (Hons) accountancy, City University of Hong Kong

Chief executive officer

Vacant since 18 Jul 2019

——

Company states it is still identifying a suitable candidate (AR2025)

Directors' Remuneration

ItemFY2025Source

Share-based compensation

Nil — no options granted under the 2024 scheme; 1.692 M legacy options (held by a customer's shareholder, not directors) lapsed on 2 Jul 2025

AR2025

Total employee benefit expense (group)

FY2024 HK$6.57 M; FY2023 HK$6.45 M

FY2024 RA note 9

Directors' Remuneration (Status (AR2025))

AttributeStatus (AR2025)

Board size

8 (3 NED, 2 ED, 3 INED)

Independence

3 of 8 (37.5%) — meets HKEX minimum of one-third

Gender

1 female director of 8 (12.5%); workforce 57% male / 43% female

Chair/CEO separation

Chair is non-executive; CEO role vacant since 2019 — executive authority sits with two EDs and the CFO

Audit committee

Wu Hung Yu (chair), Li Wei, Leung Chun Tung — all INEDs; 2 meetings in FY2025

Remuneration committee

Li Wei (chair), Yuen Chee Lap Carl, Leung Chun Tung; 1 meeting

Nomination committee

Li Wei (chair), Yuen Chee Lap Carl, Leung Chun Tung, Wu Hung Yu; 2 meetings

Board meetings / attendance

6 meetings, 100% attendance by all directors (FY2025)

Long-tenure INED

Li Wei has served >9 years (since May 2016) — under the revised HKEX CG Code (effective 1 Jul 2025), long-serving INEDs attract heightened scrutiny

Director with link to pledgee group

Chen Qi is a vice GM at Yunnan Energy Investment (HK), which owns ~40% of the parent of the pledgee of the controlling stake — a material governance linkage (AR2025)

D&O insurance

In place

Board & Management Changes

DateChangeContext

23 Aug 2024

Yuen Chee Lap Carl re-designated INED → ED

Ex-Courage Investment CEO/COO; strengthens executive bench after his departure from Courage in May 2024

21 Sep 2024

Chan Lap Kwong (陳立光) resigns as ED

Reason not captured

1 Oct 2024

Tang Yu Yuan appointed ED

Semiconductor distribution specialist

22 Nov 2024

Lin Jie (林捷) resigns as NED; Wu Hung Yu appointed INED and audit chair

Restores accounting expertise on the audit committee

25 Jun 2025

Wu Hung Yu joins nomination committee

Board diversity

17 Jun 2026

AGM re-elects retiring directors (Huang Zhiqun, Leung Chun Tung, Li Wei were scheduled to retire and stand for re-election) and re-appoints McMillan Woods

—

Pre-2023

Mr.

Interim Report 2022

Major Shareholders

HolderShares%NatureSource

Explorer Rosy Limited (Huang Zhiqun 80% / Huang Jinglin 20%)

89,248,57752.67

Beneficial owner; pledged to Yunnan International Supply Chain Ltd; receivers appointed

AR2025

Huang Zhiqun (direct)

169,0000.10

Beneficial owner

AR2025

Yunnan Provincial Energy Investment Group / Yunnan Energy Investment (HK) / Yunnan International Holding Group / Yunnan International Supply Chain

89,248,57752.67

Security interest (same shares)

AR2025

Alan C W Tang, Hou Chung Man; SHINEWING SAS (Nominee Services) No. 3 Ltd

89,248,57752.67

Joint and several receivers (same shares)

AR2025

Public float (approx.)

~80,027,423

~47.2

Company confirms sufficient public float

AR2025 (derived)

Competitive Landscape

Key Competitors

CompetitorSegment overlapTypeLatest revenueRelative positioning

Arrow Electronics (NYSE: ARW)

Electronic components

Global franchised distributor

~US$27.9 bn FY2024

~400x larger; franchise lines, design-in services

Avnet (NASDAQ: AVT)

Electronic components

Global franchised distributor

~US$22.5 bn FY2025 (Jun YE)

Same

WPG Holdings (2702.TW)

Electronic components

Asia's largest component distributor

—

Dominant Asia franchised share

WT Microelectronics (3036.TW)

Electronic components incl. memory

Asian franchised distributor

—

Memory-heavy, large scale

S.A.S. Dragon Holdings (1184.HK)

Memory and components distribution

HK-listed distributor

—

Direct HK-listed memory peer; far larger

Willas-Array Electronics (0854.HK)

Components distribution

HK-listed distributor

—

Franchised lines in HK/PRC

Shenzhen Huaqiang Industry (000062.SZ)

Components distribution & trading platforms

PRC distributor

—

Large PRC platform

VSTECS Holdings (0856.HK)

IT products distribution (adjacent)

HK-listed IT distributor

—

Adjacent; note Qianhai INED Li Wei is also INED there

Unlisted Hong Kong/Shenzhen spot-market memory traders

Electronic components

Independent brokers

—

Most direct competitors; intense price competition cited in FY2024 RA and AR2025

Hong Kong ginseng and herbal wholesalers (e.g., Sheung Wan Ko Shing Street traders; Hin Sang Group 6893.HK in health products)

Health-care

Wholesalers / consumer health

—

Qianhai now sub-scale in this segment

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricQianhai Health (FY2025)Arrow (FY2024)Avnet (FY2025)

Revenue

HK$677 M (~US$87 M)

~US$27.9 bn

~US$22.5 bn

Revenue growth

+30.3%——

Gross margin

3.5%——

Net margin

0.9%——

R&D intensity

0%

Negligible (distribution model)

Negligible

Employees

19——

Company Snapshot

$86.9M

Revenue

19

Employees

1989

Founded

Sheung Wan, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Unlevered balance sheet: no borrowings at 31 Dec 2024 and 31 Dec 2025; gearing (liabilities/assets) 4.2% (AR2025).
  • High liquidity: current ratio 22.6x at 31 Dec 2025; 8.9x at 30 Jun 2026 (AR2025; 1H2026 IR).
  • Experienced sector insiders: chairman with 20+ years in component trading; ED Tang with 28+ years in semiconductor distribution (AR2025).
  • Lean cost base: administrative expenses HK$15.3 M in FY2024 and HK$6.8 M in 1H2026 (−27.9%) (FY2024 RA; 1H2026 IR).
  • Demonstrated ability to restore gross margin: from −3.7% (FY2023) to 5.7% (FY2024) and 6.6% (1H2026) (FY2024 RA; 1H2026 IR).
  • Consistent profitability since FY2024: four consecutive profitable half-years (1H2024 through 1H2026), albeit small (various RAs).
  • Distributable reserves of HK$258.4 M provide capacity for future distributions (AR2025).

Weaknesses

  • Extreme customer concentration: top customer ~69%, top five ~92% of FY2025 sales (AR2025).
  • Supplier concentration: top five suppliers ~90% of FY2025 purchases (AR2025).
  • Wafer-thin margins: FY2025 gross margin 3.5%, net margin 0.9% (AR2025).
  • No franchise rights / allocation: volumes fell in FY2025 despite price surge "due to industry-wide shortage" (AR2025).
  • Leadership gap: CEO vacant since 18 Jul 2019 (AR2025).
  • Poor long-run returns: cumulative net losses of ~HK$280 M FY2021–FY2023; ROE ≤1.5% since (analyst-derived from ARs).
  • Receivables quality: trade receivables up 126% to HK$222.7 M in FY2025; ECL provision up to HK$2.6 M (AR2025).

Opportunities

  • Memory super-cycle: WSTS's June 2026 forecast of memory revenue up ~250% in 2026 to >US$800 bn (WSTS).
  • Inventory positioned for higher prices: inventory rebuilt to HK$231.4 M at 30 Jun 2026 (1H2026 IR) — would generate trading gains if spot prices keep rising.
  • Downstream value-add: proposed packaging/testing/customisation facilities could lift margins (AR2025).
  • Health-care revival: ginseng wine and skin-care; 1H2026 health-care revenue +29.5% (1H2026 IR).
  • Discount to book: P/B ~0.26–0.31x (Lixinger; analyst-derived) offers scope for value realisation via a change of control or asset-backed transaction.
  • Stock Connect eligibility: ~4% held via Southbound Connect, widening the investor base (Lixinger).

Threats

  • Memory price reversal: FY2022 inventory provision HK$230.0 M and onerous-contract provision HK$93.2 M (8 Feb 2024 inside information).
  • Continued allocation squeeze: 1H2026 revenue −65.7% as capacity shifts to HBM/DDR5 (1H2026 IR).
  • Change of control via receivership: receivers appointed over 52.67% (AR2025).
  • Legacy litigation: CAD 2.8 M (~HK$14.8 M) Canadian supplier claim with no provision; Beijing court dispute involving a disposed subsidiary (AR2025; FY2024 RA).
  • Customer credit event: concentration plus 30–180 day terms (AR2025).
  • Share-price manipulation / speculation risk: intraday moves exceeding 100% in April 2026 (etnet) could attract regulatory scrutiny.
  • Geopolitical/export controls affecting semiconductor flows through Hong Kong (AR2025 acknowledges geopolitical supply risk).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 Nov 2024Disposal of Huge Hope Group completedRemoves HK$134.2 M onerous contracts; HK$51.9 M gain
6 & 20 Dec 2024Disposal announcements publishedDiscloseable transaction
6 Mar 2025Positive profit alert: FY2024 profit ~HK$1.3 M vs FY2023 loss HK$52.7 M; cites higher-margin mix, disposal gain, ~HK$54 M onerous-contract provision on Q4 2024 price fallsTurnaround signal
24 Mar 2025FY2024 annual results: revenue HK$519.7 M, profit HK$1.3 M, no dividendFirst profit since FY2020
28 Apr 2025AR2024 published—
27 May 2025AGM circular (re-election of retiring directors)—
25 Jun 2025AGM — all resolutions passed by poll (e.g., director remuneration resolution 89,263,602 votes for, 100%)Controlling block votes
25 Jun 2025Wu Hung Yu appointed to nomination committeeGovernance
2 Jul 2025Remaining 1.692 M legacy share options lapseNo options outstanding
28 Jul 2025Profit-related announcement for 1H2025 (title truncated in data source; consistent with a profit warning given the subsequent 69% decline)Earnings pressure
6 Aug 2025Board meeting notice for interim results—
20 Aug 20251H2025 results: revenue ~HK$341 M (+11.0%), gross profit HK$14.2 M (from HK$42.9 M), profit HK$4.77 M (−69.3%), EPS 2.82 centsMargin compression from competition
29 Sep 2025Interim Report 2025 published—
19 Dec 2025Supplementary announcement to FY2024 annual results and annual report–
Monthly, Jan–Jul 2026Monthly returns: issued shares unchanged at 169,445,000No dilution
13 Feb 2026Positive profit alert: FY2025 profit to rise substantially (to up to ~HK$6.0 M)Upside surprise
4 Mar 2026Board meeting notice for annual results—
18 Mar 2026FY2025 annual results: revenue HK$677.1 M (+30.3%), profit HK$5.94 M (~3.5x), no dividendBest result since FY2019
24 Apr 2026Start of unusual trading activity (market alerts)Volatility
27 Apr 2026Shares more than double intraday to HK$0.84No company explanation captured
28 Apr 2026Shares fall >20% to HK$0.79—
29 Apr 2026Shares surge >100% intraday to HK$1.22; AR2025 published same dayPeak of speculative move
29 Apr 2026AR2025 discloses receivers appointed over the 52.67% controlling stake pledged to Yunnan International Supply ChainPotential change of control
12 May 2026AGM notice; re-election of Huang Zhiqun, Leung Chun Tung, Li Wei; re-appointment of auditor—
17 Jun 2026AGM held; poll results announced—
Early Jul 2026Share price ~HK$0.66–0.72; Stock Connect holds ~4%Mainland investor participation
15 Jul 2026Shares +8% to HK$0.81—
24 Jul 2026Profit warning: 1H2026 profit expected to fall 35–45%Guidance
29 Jul 2026Board meeting notice for interim results; shares HK$0.61—
12 Aug 20261H2026 results: revenue HK$116.8 M (−65.7%), gross margin 6.6%, profit HK$2.84 M (−36.7%), inventory HK$231.4 M, cash HK$17.9 M; no interim dividendSupply shortage hits volume; renewed inventory build
Sep 2026 (expected)Interim Report 2026 publication (statutory deadline end-September)–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 283.4 Mn in FY2021 to HKD 677.1 Mn in FY2025.
Qianhai Health Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue283.41,961.7961.3519.7677.1
Cost of sales267.41,885.2996.9490653.5
Gross profit1676.5-35.629.723.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Annual Report 2025 (published 29 Apr 2026) (hkexnews.hk)
  2. Annual Results Announcement FY2024 (24 Mar 2025) (www1.hkexnews.hk)
  3. Annual Report 2024 (Chinese, 28 Apr 2025) (hkexnews.hk)
  4. Annual Results Announcement FY2023 (14 Mar 2024) (www1.hkexnews.hk)
  5. Annual Report 2023 (www1.hkexnews.hk)
  6. Inside information — reduced FY2023 loss (8 Feb 2024) (hkexnews.hk)
  7. Annual Report 2022 (www1.hkexnews.hk)
  8. Annual Results Announcement FY2022 (www1.hkexnews.hk)
  9. Annual Report 2021 (www1.hkexnews.hk)
  10. Annual Report 2020 (hkexnews.hk)
  11. Annual Results Announcement FY2020 (www1.hkexnews.hk)
  12. Annual Results Announcement FY2019 (www1.hkexnews.hk)
  13. Annual Report 2019 (hkexnews.hk)
  14. Annual Report 2018 (hkexnews.hk)
  15. Annual Report 2017 (hkexnews.hk)
  16. Annual Report 2016 (hkexnews.hk)
  17. Interim Results 1H2024 (www1.hkexnews.hk)
  18. Interim Results 1H2023 (www1.hkexnews.hk)
  19. Interim Results 1H2022 (www1.hkexnews.hk)
  20. Interim Report 2022 (www1.hkexnews.hk)
  21. Positive profit alert 1H2022 (www1.hkexnews.hk)
  22. Positive profit alert FY2024 (Chinese, 6 Mar 2025) (newsfile.moomoo.com)
  23. AGM poll results 25 Jun 2025 (Chinese) (hkexnews.hk)
  24. 1H2025 results summary (Tiger Brokers, 20 Aug 2025) (itiger.com)
  25. 1H2026 results summary (Tiger Brokers, 12 Aug 2026) (itiger.com)
  26. AR2025 publication summary (Webull/PUBT, 29 Apr 2026) (webull.hk)
  27. etnet announcements and market news for 00911: and: etnet.com.hk · etnet.com.hk
  28. Lixinger quote and CCASS holdings: and: lixinger.com · lixinger.com
  29. moomoo company profile (moomooapp.com)
  30. Finnomena company profile (finnomena.com)
  31. TipRanks financial aggregates: and: tipranks.com · tipranks.com
  32. TipRanks — subsidiary disposal summary (tipranks.com)
  33. WSTS Autumn 2025 forecast (wsts.org)
  34. WSTS June 2026 forecast (via AnySilicon) (anysilicon.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.